The diagnostic pathway of Alzheimer's disease in real-world clinical practice in Spain: results from the Adelphi Dementia Disease Specific Programme™
The diagnostic process for people with MCI and AD could be accelerated by increased awareness of the disease, shorter referral times, and better access to specialized diagnostic services. This study shows limited use of AD-specific biomarker testing in Spain.
Authors
- D Novick
- Enrique Arrieta
- Sarah Cotton (ORCID: https://orcid.org/0000-0003-1158-6345)
- Pablo Gregorio Baz
- Mercedes Granados Nuñez
- Chloe Walker (ORCID: https://orcid.org/0009-0000-5643-6725)
- Silvia Díaz-Cerezo
- Ángel Trueba Saiz
- Pascual Sánchez-Juan
Institutions
- Eli Lilly (United States) (US)
- Instituto de Salud Carlos III (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Hospital General De Segovia (ES)
- Adelphi Group (United Kingdom) (GB)
- Centro de Investigación Biomédica en Red (ES)
- Ministerio de Salud Pública (CU)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/fneur.2025.1702805
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company